SG10201913366QA - Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof - Google Patents

Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof

Info

Publication number
SG10201913366QA
SG10201913366QA SG10201913366QA SG10201913366QA SG10201913366QA SG 10201913366Q A SG10201913366Q A SG 10201913366QA SG 10201913366Q A SG10201913366Q A SG 10201913366QA SG 10201913366Q A SG10201913366Q A SG 10201913366QA SG 10201913366Q A SG10201913366Q A SG 10201913366QA
Authority
SG
Singapore
Prior art keywords
neoplastic cell
converting
pharmaceutical association
neoplastic
cell
Prior art date
Application number
SG10201913366QA
Other languages
English (en)
Inventor
Omar F Zouani
Veronika Gocheva
Original Assignee
Histide Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Histide Ag filed Critical Histide Ag
Publication of SG10201913366QA publication Critical patent/SG10201913366QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • C12N2310/531Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10201913366QA 2015-09-17 2016-09-15 Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof SG10201913366QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562219728P 2015-09-17 2015-09-17

Publications (1)

Publication Number Publication Date
SG10201913366QA true SG10201913366QA (en) 2020-02-27

Family

ID=56936411

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201913366QA SG10201913366QA (en) 2015-09-17 2016-09-15 Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof

Country Status (17)

Country Link
US (1) US20190290729A1 (da)
EP (3) EP3349776B1 (da)
JP (2) JP7236134B2 (da)
KR (1) KR20180050744A (da)
CN (1) CN109715190A (da)
AU (1) AU2016323407A1 (da)
CA (1) CA2998297A1 (da)
DK (1) DK3349776T3 (da)
ES (1) ES2862103T3 (da)
HR (1) HRP20210441T1 (da)
HU (1) HUE053697T2 (da)
IL (2) IL299622A (da)
LT (1) LT3349776T (da)
PL (1) PL3349776T3 (da)
SG (1) SG10201913366QA (da)
SI (1) SI3349776T1 (da)
WO (1) WO2017046227A2 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3341398A2 (en) 2015-08-25 2018-07-04 Histide AG Compounds for inducing tissue formation and uses thereof
WO2017046228A2 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof
US11299513B2 (en) 2017-07-28 2022-04-12 Circle Pharma, Inc. Cyclative release of peptidic compounds
CN116204770B (zh) * 2022-12-12 2023-10-13 中国公路工程咨询集团有限公司 一种用于桥梁健康监测数据异常检测的训练方法及装置

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US20030185792A1 (en) 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
US5846536A (en) * 1996-10-04 1998-12-08 The Regents Of The University Of California Restoration of normal phenotype in cancer cells
DE19748688C2 (de) * 1997-04-22 2001-09-06 Hans Georg Graeber Membransystem zur gesteuerten Geweberegeneration bei Erkrankungen des Zahnhalteapparates
US20040023322A1 (en) * 2002-08-01 2004-02-05 Goodheart Clyde R. Method of producing non-recombinant BMP-2 and use thereof
WO2005030933A2 (en) * 2003-09-24 2005-04-07 Genera Doo Bone morphogenetic protein (bmp)-7 based diagnosis and treatment of cancer
US7528105B1 (en) * 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
WO2006078161A1 (en) * 2005-01-24 2006-07-27 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
DK1904093T3 (da) * 2005-07-19 2018-09-03 Stemgen S P A Inhibering af det tumorigene potentiale af tumorstamceller med bmp-4
WO2007114851A1 (en) * 2006-04-04 2007-10-11 The Board Of Trustees Of The University Of Illinois Methods and compositions to induce cell death of invasive tumors
US7998740B2 (en) * 2006-07-18 2011-08-16 Robert Sackstein Cytokine induction of selectin ligands on cells
GB0615129D0 (en) * 2006-07-29 2006-09-06 Univ Cardiff Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
KR100894265B1 (ko) * 2007-06-05 2009-04-21 재단법인서울대학교산학협력재단 골형성 촉진 펩타이드를 함유하는 주입형 골재생재
AU2008282331A1 (en) * 2007-07-27 2009-02-05 Facet Biotech Corporation Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (CD49E)
CN103561761A (zh) * 2011-03-23 2014-02-05 加利福尼亚大学董事会 用于使用抗-整合素改善抗血管生成疗法的方法和组合物
SG10201800800YA (en) * 2013-05-06 2018-03-28 Scholar Rock Inc Compositions and methods for growth factor modulation

Also Published As

Publication number Publication date
LT3349776T (lt) 2021-03-25
CA2998297A1 (en) 2017-03-23
AU2016323407A1 (en) 2018-04-19
IL299622A (en) 2023-03-01
EP3906932A2 (en) 2021-11-10
HRP20210441T1 (hr) 2021-04-30
ES2862103T3 (es) 2021-10-07
JP2018536623A (ja) 2018-12-13
WO2017046227A3 (en) 2017-06-29
EP3349776A2 (en) 2018-07-25
IL258131A (en) 2018-05-31
US20190290729A1 (en) 2019-09-26
SI3349776T1 (sl) 2021-04-30
IL258131B2 (en) 2023-06-01
JP2023027372A (ja) 2023-03-01
JP7236134B2 (ja) 2023-03-09
EP3349776B1 (en) 2020-12-30
EP3875102A1 (en) 2021-09-08
WO2017046227A2 (en) 2017-03-23
EP3906932A3 (en) 2021-12-01
CN109715190A (zh) 2019-05-03
HUE053697T2 (hu) 2021-07-28
DK3349776T3 (da) 2021-03-22
PL3349776T3 (pl) 2021-08-02
KR20180050744A (ko) 2018-05-23

Similar Documents

Publication Publication Date Title
IL254414A0 (en) Systems and methods for mobile capsule dispensers
SG10201913394SA (en) Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof
SG11201705807UA (en) Stacking and dispensing module
GB2544569B (en) Improvements in tablet manufacture
ZA201703976B (en) Dihydropyrimidine-2-one compounds and medicinal uses thereof
GB201412320D0 (en) Mobile digestion plant
PL3209582T3 (pl) Silos, wyposażenie i sposób budowy silosu
SG10201913380WA (en) Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof
SG10201913366QA (en) Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof
SG11201602828YA (en) Material and structures for cell delivery
SG10201913355RA (en) Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof
HUE046373T2 (hu) Gyógyszercsomagolás
EP3174115A4 (en) Charge transport material
EP3164664A4 (en) A shell for use in blasting
SG11201803227QA (en) Swivel stack
GB2555033B (en) A lithium-sulphur cell
PT3153505T (pt) Novos bis-indolilmetanos, um processo para a sua preparação e utilizações dos mesmos
HK1251863A1 (zh) 可碼放容器
ZA201800972B (en) Methanogenesis
SG10202111096SA (en) Process for preparing a crassocephalum crepidioides extract, extract prepared thereby and use of the extract
PT3023093T (pt) Preparação medicinal à base de diosmectite
GB201414789D0 (en) Stack interchange
SG10201404227SA (en) Stack interchange
GB201406586D0 (en) Full cell stack arrangement
AU2014902561A0 (en) A Fence Clasp